Lisata Therapeutics, Inc
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors. The company is built around its CendR Platform and is currently pre-commercial, with development activity centered on oncology and other major diseases.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of certepetide and related oncology programs intended to improve treatment penetration in solid tumors.
The CendR Platform® is the core enabling technology used to activate active transport into tumors.
Upfront fees and partner-funded research arrangements tied to preclinical and clinical development.
Customers
Lisata does not yet sell approved medicines, so its near-term counterparties are research partners, licensors, and clinical collaborators rather than end patients. If approved, its commercial customers would be physicians, hospitals, cancer centers, and payors that decide whether certepetide-based regimens are adopted and reimbursed.
Companies or institutions that pay upfront fees or collaborate on development using the CendR Platform.
Trial sites and research organizations that execute studies needed to advance certepetide.
Physicians, hospitals, and cancer centers that would prescribe or administer the therapy if approved.
Insurers and government programs that would influence access, pricing, and reimbursement.
Strategy
The company’s strategy is to advance certepetide through clinical development, secure regulatory approvals, and build evidence that the platform improves delivery of existing cancer therapies. Near term, it is also focused on preserving liquidity through partnerships, grants, and other non-dilutive funding while it evaluates strategic transactions, including the announced acquisition by Kuva Labs.
Clinical data are needed to validate the platform and support regulatory filings.
The company has operating losses and needs external funding to continue development.
Partnerships can provide funding, validation, and a route to market without building a full sales force.
Geography
Lisata is headquartered in the United States but conducts operations through an Australian subsidiary, which creates a meaningful international operating footprint. Its development and commercialization plans are global in nature, but the company currently has no sales infrastructure and remains dependent on clinical, regulatory, and partnership activity rather than product revenue.
Risks
Lisata faces the classic risks of a clinical-stage biotech: trial failure, regulatory setbacks, reimbursement uncertainty, and the need to raise capital before any meaningful product revenue exists. Company-specific risks also include dependence on an Australian subsidiary, cybersecurity and contractor execution risk, and uncertainty around the proposed Kuva acquisition.
- Clinical development failureImpact: CriticalLikelihood: High
Certepetide is investigational, so negative trial data would impair the platform and future value.
Exposure: Phase 2a and later-stage oncology studies
- Liquidity and going-concern riskImpact: CriticalLikelihood: High
Operating losses and limited revenue mean continued funding is required to sustain operations.
Exposure: Cash runway and future financings
- Regulatory approval riskImpact: HighLikelihood: High
The company has no approved products, and approval is required before commercialization.
Exposure: US and ex-US oncology regulators
- Commercial reimbursement riskImpact: HighLikelihood: Medium
Even if approved, uptake depends on coverage and pricing by payors and health systems.
Exposure: US managed care and government reimbursement
- Transaction execution riskImpact: MediumLikelihood: High
The proposed Kuva acquisition is subject to closing conditions and could fail or be delayed.
Exposure: Merger process and Nasdaq delisting
- International subsidiary and tax riskImpact: MediumLikelihood: Low
Operations through Australia could be affected by tax-credit eligibility or local operating changes.
Exposure: Australian subsidiary
Accounting
Judgemental itemsThe company reported $70k of revenue tied to an upfront research license fee, so timing and performance obligations matter.
Impact: Can cause uneven quarterly revenue
R&D expense depends on estimates for patient treatment, CRO, and CMC costs not yet invoiced.
Impact: Affects operating loss and comparability
Equity awards have historically been used to conserve cash and create non-cash expense.
Impact: Inflates reported operating costs without cash outflow
Management disclosed substantial doubt about continuing as a going concern within 12 months.
Impact: Signals financing dependence and balance-sheet risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Guided Therapeutics Inc
GTHP · Electromedical & Electrotherapeutic Apparatus
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Dermata Therapeutics, Inc.
DRMA · Pharmaceutical Preparations
Last updated: 24/09/2026